Johnson & Johnson — Wall Street Analyst Estimates & Price Targets

JNJ

NYSEHealthcareDrug Manufacturers - GeneralCIK 0000200406jnj.comAbout JNJ

Last close · Oct 16, 2026255.56+2.28 (+0.90%)

Market cap$615.9B

10 firms' latest targets, last 90 days: median $280.00 ($270.00–$320.00), 10% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 10 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-16	Wells Fargo	$287.00	$275.00	▲ 4%	+13%	+12%
2026-10-15	Bernstein	$270.00	$208.00	▲ 30%	+4%	+6%
2026-10-14	RBC Capital	$280.00	$290.00	▼ 3%	+11%	+10%
2026-10-14	Leerink Partners	$272.00	$265.00	▲ 3%	+8%	+6%
2026-10-14	UBS	$270.00	$320.00	▼ 16%	+9%	+6%
2026-09-29	New Street	$278.00	—	—	+2%	+9%
2026-09-10	HSBC	$320.00	$290.00	▲ 10%	+20%	+25%
2026-08-06	Guggenheim	$287.00	$270.00	▲ 6%	+11%	+12%
2026-08-03	Raymond James	$280.00	$265.00	▲ 6%	+10%	+10%
2026-07-29	Argus Research	$300.00	—	—	+13%	+17%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$85.2B	-10%	$13.72	+104%	est. $84.7B+0%	est. $9.92	10
2024reported	$88.8B	+4%	$5.79	-58%	est. $88.8B+0%	est. $9.95	13
2025reported	$94.2B	+6%	$11.03	+91%	est. $93.8B+0%	est. $10.80	15
2026	$101.2B	+7%	$11.19	+4%	$100.8B–$101.9B	$11.05–$11.67	15
2027	$108.2B	+7%	$11.85	+6%	$105.9B–$109.5B	$11.09–$12.59	15
2028	$116.9B	+8%	$14.00	+18%	$114.0B–$120.2B	$13.20–$15.28	16
2029	$125.7B	+8%	$15.85	+13%	$124.1B–$127.4B	$15.59–$16.12	11
2030	$135.4B	+8%	$17.83	+13%	$133.7B–$137.2B	$17.54–$18.14	11

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$280.00median target, 10% above the last close

Firms with a target · last 90 days: 10
Lowest – highest target: $270.00 – $320.00
Current grades of 18 firms: positive / neutral / negative: 12 / 6 / 0
Upgrades / downgrades · 12 months: 2 / 1
Consensus revenue growth · next 3 FY: +7% a year

Current grades

each firm's latest · 18 firms

As of	Firm	Grade
2026-10-15	Morgan Stanley	“Overweight”
2026-10-14	Leerink Partners	“Outperform”
2026-10-14	Wells Fargo	“Overweight”
2026-10-14	RBC Capital	“Outperform”
2026-10-07	Guggenheim	“Buy”
2026-10-05	Citigroup	“Buy”
2026-09-29	J.P. Morgan	“Neutral”
2026-09-10	HSBC	“Buy”
2026-09-02	UBS	“Buy”
2026-07-16	Raymond James	“Outperform”

8 more

2026-07-13	TD Cowen	“Buy”
2026-07-10	Bank of America	“Neutral”
2026-04-15	Barclays	“Equal Weight”
2026-04-15	Stifel	“Hold”
2026-01-27	Freedom Capital Markets	“Hold”
2026-01-22	Scotiabank	“Sector Outperform”
2026-01-09	Bernstein	“Market Perform”
2025-12-19	Goldman Sachs	“Buy”

Grade changes

last 24 months · 7

Date	Firm	Grade
2026-05-13	Leerink Partners	“Market Perform” → “Outperform” upgrade
2026-01-28	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2025-10-22	Freedom Capital Markets	“Buy” → “Hold” downgrade
2025-10-03	Wells Fargo	“Equal Weight” → “Overweight” upgrade
2025-09-23	Guggenheim	“Neutral” → “Buy” upgrade
2025-05-13	Leerink Partners	“Outperform” → “Market Perform” downgrade
2025-04-09	Goldman Sachs	“Neutral” → “Buy” upgrade

43 older than 24 months

2024-07-23	Daiwa Capital	“Outperform” → “Neutral” downgrade
2024-04-18	HSBC	“Hold” → “Buy” upgrade
2023-12-13	Wells Fargo	“Overweight” → “Equal Weight” downgrade
2023-12-01	UBS	“Neutral” → “Buy” upgrade
2022-03-16	Bernstein	“Outperform” → “Market Perform” downgrade
2021-09-07	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2020-07-20	Independent Research	“Hold” → “Buy” upgrade
2020-04-28	UBS	“Buy” → “Neutral” downgrade
2020-04-22	Bank of America	“Neutral” → “Buy” upgrade
2019-12-19	Barclays	“Equal Weight” → “Overweight” upgrade
2019-12-17	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2019-10-16	Atlantic Equities	“Underweight” → “Neutral” upgrade
2019-10-11	Bernstein	“Market Perform” → “Outperform” upgrade
2018-07-12	Goldman Sachs	“Sell” → “Neutral” upgrade
2018-06-27	Bernstein	“Market Perform” → “Perform” revised
2018-05-05	Argus	“Hold” → “Buy” upgrade
2018-01-02	J.P. Morgan	“Overweight” → “Neutral” downgrade
2017-10-11	Jefferies	“Hold” → “Buy” upgrade
2017-10-09	Wells Fargo	“Market Perform” → “Outperform” upgrade
2017-09-20	Goldman Sachs	“Neutral” → “Sell” downgrade
2017-07-21	BTIG Research	“Neutral” → “Sell” downgrade
2017-07-21	Atlantic Equities	“Neutral” → “Underweight” downgrade
2017-05-15	J.P. Morgan	“Neutral” → “Overweight” upgrade
2017-01-26	Wells Fargo	“Outperform” → “Market Perform” downgrade
2016-11-29	Barclays	“Overweight” → “Equal Weight” downgrade
2016-07-20	Argus Research	“Hold” → “Buy” upgrade
2016-05-12	BTIG	“Buy” → “Neutral” downgrade
2016-03-14	Goldman Sachs	“Sell” → “Neutral” upgrade
2015-12-01	Barclays	“Equal Weight” → “Overweight” upgrade
2015-09-29	Deutsche Bank	“Hold” → “Buy” upgrade
2015-01-15	Goldman Sachs	“Neutral” → “Sell” downgrade
2014-10-01	Bernstein	“Market Perform” → “Perform” revised
2014-04-14	Jefferies	“Buy” → “Hold” downgrade
2014-01-10	Barclays	“Overweight” → “Equal Weight” downgrade
2014-01-09	Jefferies	“Hold” → “Buy” upgrade
2014-01-07	RBC Capital	“Sector Perform” → “Outperform” upgrade
2013-10-11	Goldman Sachs	“Sell” → “Neutral” upgrade
2013-07-17	Deutsche Bank	“Buy” → “Hold” downgrade
2013-04-08	J.P. Morgan	“Overweight” → “Neutral” downgrade
2013-02-07	Credit Suisse	“Neutral” → “Underperform” downgrade
2013-01-04	Deutsche Bank	“Hold” → “Buy” upgrade
2012-12-10	Davenport	“Neutral” → “Hold” revised
2012-11-12	Jefferies	“Buy” → “Hold” downgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.